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Potential blood pressure- (BP-) lowering mechanisms of the DASH dietary pattern were measured in 20 unmedicated hypertensive
adults in a controlled feeding study. At screening, participants averaged 44.3 ± 7.8 years, BMI 33.9 ± 6.6Kg/m2, and BP 144.2 ±
9.38/88.5 ± 6.03mmHg. All consumed a control diet for one week, then were randomized to control or DASH for another two
weeks (week one and two).With DASH, but not controls, SBP fell by 10.65±12.89 (P = 0.023) and 9.60±11.23 (P = 0.039)mmHg
and DBP by 5.95± 8.01 (P = 0.069) and 8.60± 9.13mmHg (P = 0.011) at the end of week one and two, respectively. Univariate
regressions showed that changes in urinary sodium/potassium ratio (β = 1.99) and plasma renin activity (β = −15.78) and
percent change in plasma nitrite after hyperemia were associated with SBP changes at week one (all P < 0.05). Plasma nitrite
following hyperemia showed a treatment eﬀect (P = 0.014) and increased at week two (P = 0.001). Pulse wave velocity decreased
over time with DASH (trend P = 0.019), and reached significance at week two (P = 0.026). This response may be mediated
by an improvement in upregulation of nitric oxide bioavailability. Early natriuresis and reductions in oxidative stress cannot be
ruled out. Future studies are needed to verify these findings, assess the possibility of earlier eﬀects, and examine other potential
mediators.
1. Introduction
Randomized, controlled feeding trials have established the
blood pressure- (BP-) lowering eﬀects of the Dietary Ap-
proaches to Stop Hypertension (DASH) dietary pattern
[1, 2], which emphasizes fruits, vegetables, and low-fat dairy
and is low in meats, sugar-sweetened beverages, and satu-
rated and total fat. These original DASH studies were de-
signed to establish eﬃcacy, not to determine the mechanism
of action. Postulated mechanisms for the BP-lowering eﬀect
of the DASH dietary pattern include eﬀects on the natriure-
sis, renin-angiotensin-aldosterone system (RAAS), reduced
adrenergic tone, and increased vascular relaxation [3–6]. To
date, these mechanisms have not been directly evaluated.
An understanding of the mechanism(s) by which the DASH
dietary pattern lowers BP can potentially enhance the eﬃcacy
of this dietary intervention by elucidating the conditions
under which it will be most eﬀective and help to identify
target populations who may receive optimal benefits. It may
also help to define interactions or synergistic eﬀects with
other concurrent BP interventions such as pharmacotherapy.
Therefore, the overall goal of this pilot project was to de-
termine the mechanism(s) by which the DASH dietary pat-
tern lowers BP in unmedicated hypertensive individuals.
2. Patients and Methods
2.1. Study Design. This study was a randomized controlled
feeding trial testing the eﬀects of two dietary patterns on
sodium excretion, plasma renin activity, aldosterone, cate-
cholamines, and markers of vascular endothelial function.
The design and flow of the study is illustrated in Figure 1.
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45 eligible, 5 no show or other
conflict, 40 attended second
clinic visit.
25 eligible for feeding, 2
dropped before feeding started
due to starting meds and other
conflict.
10 randomized to
DASH diet group,
week 1
23 started feeding, all
consumed the typical control
diet for one week.
10 randomized to
control diet group,
week 1
1 dropped due to
time conflict, 9
continued the
control diet group,
10 continued the
DASH diet group,
week 2
32 ineligible due to
BP or other
criteria.
15 ineligible due
to BP or other
criteria.
3 dropped before
randomization due
to personal conflict.
Baseline
measurement
Week 2
measurement
Week 1
measurement
Measurement
schedule
91 cannot be
reached, refused,
or other conflict.
63 ineligible due to
BP meds, low BP,
or other screening
criteria.
106 eligible, 29 discontinued
screening due to time conflict,
relocation, or no show, 77
attended first clinic visit.
week 2
n = 260 responded to study
ads.
N = 169 attended pre
screening visits.
Figure 1: Design and flow of study.
The study was approved by the Duke University Medical
Center Institutional Review Board, and all participants pro-
vided written informed consent prior to participation. After
screening, participants started the controlled feeding proto-
col. For the first week (run-in), all participants consumed a
typical American (control) diet (Table 1). Participants were
then randomly assigned to either continue with the control
diet or switch to the DASH dietary pattern. Since the BP-
lowering eﬀect of the DASH dietary pattern is maximal after
two weeks of controlled feeding [1], participants in the
current trial ate the assigned dietary pattern for two weeks
after randomization. Outcomes were measured at the end of
run-in and at the end of week one and week two of the ran-
domized feeding.
2.2. Study Participants. Participants were included in the
study if they were age 22 yrs or older, stage 1 hypertensive
(average SBP 140–159 and DBP 90–99mmHg over two
screening visits), not taking BP medication for at least 3
months prior to screening, had a BMI within 18.5–40 kg/m2,
not pregnant or nursing, and willing to be randomized to
either of the treatment groups. Exclusion criteria included
secondary hypertension, diabetes requiring insulin or hypo-
glycemic agents, special dietary requirements incompatible
Table 1: Nutrient composition of the two dietary assignments.1
Nutrients DASH Control
Energy (kcal) 2100 2100
Total fat (% kcal) 27 34
Saturated fatty acids (% kcal) 4 13
Monounsaturated fatty acids (% kcal) 15 13
Polyunsaturated fatty acids (% kcal) 8 8
Protein (% kcal) 18 15
Carbohydrate (% kcal) 56 49
Cholesterol (mg) 150 300
Fiber (g) 32 11
Potassium (mg) 4700 1700
Magnesium (mg) 500 160
Calcium (mg) 1250 450
Sodium (mg) 3400 3400
1
All data based on daily energy intake of 2100 kcal. Percentages for
macronutrients (fats, protein, and carbohydrate) remained the same for all
caloric levels. Other target nutrients including fiber, potassium, magnesium,
calcium, and sodium were proportional to caloric intake.
with study diets, comorbid medical condition such as active
cancer, heart or lung disease, kidney disease (estimated
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GFR < 60mL/min), or other major illness, consuming more
than 14 alcoholic drinks per week, or major psychiatric
disorder. All potential participants completed a phone pre-
screening interview first to establish major eligibility criteria,
and then attended two face-to-face screening visits to further
establish eligibility and obtain pre-run-in measures.
2.3. Intervention
2.3.1. Content of the Dietary Patterns. The nutrient profiles
of the two diets are presented in Table 1 and were consistent
with previous DASH trials. Specifically, the DASH dietary
pattern emphasized fruits, vegetables, and low-fat dairy
foods, included whole grains, poultry, fish, and nuts and
was reduced in fats, red meat, sweets, and sugar-containing
beverages [7]. Relative to the typical American control diet,
DASH was reduced in total and saturated fat and cholesterol
and increased in potassium, calcium, magnesium, dietary
fiber, and protein. The composition of the control diet was
based on the profile reported in the NHANES III survey [8]
and contained relatively high total and saturated fat and cho-
lesterol and lower fruits, vegetables, and low fat dairy prod-
ucts. In order to isolate the eﬀects of the DASH dietary pat-
tern, sodium intake for both diets was the same (3400mg/
2100 kcal/day), comparable to typical US consumption as
estimated by NHANES III.
This study employed the same controlled feeding pro-
tocol and followed the same quality assurance procedures
used in the DASH and the DASH-sodium multicenter trials
[1, 2]. All foods and beverages for each participant were
purchased and prepared in themetabolic kitchen at the Sarah
W. Stedman Nutrition and Metabolism Center. As in the
DASH studies, participants consumed the main meal of the
day at the Stedman Center from Monday to Friday under the
supervision of the study staﬀ and took home the rest of the
foods as “to go” packages. Adherence was assessed by direct
observation by the supervising staﬀ during on-site meals and
by a questionnaire completed daily on which participants in-
dicated if they failed to eat any of the “take home” study foods
or ate any foods that were not provided by the study.
At the beginning of the study, energy (calorie) require-
ment for each participant was estimated by using the WHO
formula adjusted with a physical activity factor estimated
from a seven-day physical activity questionnaire [9]. During
feeding, body weight was monitored daily, and caloric intake
was adjusted quickly to maintain constant weight during the
entire study period.
Randomization occurred electronically in the middle of
the run-in period to allow time for kitchen staﬀ to prepare
foods. Participants were not notified of their randomization
assignment but were likely to infer it when they received the
first meal of the randomized feeding. The inability to fully
blind study participants to treatment assignment is a known
and unavoidable limitation of most feeding studies.
2.4. Measurements. All study measurements were performed
by trained, certified study personnel during face-to-face clin-
ic visits. The study personnels who obtained these measure-
ments were blinded to intervention assignments. BP was
measured in a standardized manner, using an automated
device [1]. At the beginning of each visit, participants rested
quietly for five minutes in the seated position with a back
rest. An appropriately sized cuﬀ was applied to the right
arm after measurement of arm circumference. The auto-
matic sphygmomanometer device was activated, and a BP
measurement was recorded. Second and third readings were
obtained, each after a 30-second rest period. The last two BP
measurements from each visit were averaged to determine
BP at the end of run-in (baseline) and subsequent follow-
up visits. Body weight was measured in light indoor clothes
without shoes to the nearest 0.1 kg using a high-quality
digital scale.
Dietary intake prior to the study was assessed by collect-
ing a four-day food record during screening, a commonly
used reference method for diet assessment [10, 11], and the
records were analyzed with the Nutrition Data System
(NDSR). Twenty-four-hour urine collections were aliquoted
and sent to LabCorp for assessment of urinary sodium (Na+),
potassium (K+), calcium (Ca++), magnesium (Mg++), phos-
phorous (P), creatinine, and urea nitrogen excretion. In
steady state, urinary K+, P, and urea nitrogen serve asmarkers
of dietary intake of fruits and vegetables, dairy, and protein,
respectively. Potential mediators of DASH BP response were
measured after an overnight fast (except for 24-hour urine
collections) and included the following.
(i) Natriuresis was assessed by 24-hour urinary excretion
of Na+.
(ii) Plasma renin activity (PRA) and aldosterone were as-
sayed in a high-quality commercial clinical lab (LabCorp)
from fasting blood samples collected after participants were
in sitting position for at least 15 minutes.
(iii) Urinary catecholamines (epinephrine and norepi-
nephrine) were analyzed from the 24-hour urinary specimen
by HPLC with electrochemical detection in a research labo-
ratory at Duke [12].
(iv) Plasma nitric oxide (NO) metabolite analysis was
performed on blood taken from the median-cubital vein in
the test arm at rest and 60 sec following an upper arm occlu-
sion for 5 minutes. Briefly, the blood samples were drawn
into an untreated syringe and mixed with 1 : 1000 heparin
at a ratio of 1mL blood to 5 uL heparin. The plasma was
separated out and frozen in liquid nitrogen immediately fol-
lowing collection and then stored at −80◦C until assayed for
various NO metabolites by reductive chemiluminescence
[13].
(v) Vascular endothelial function was measured by bra-
chial artery flow-mediated dilation (BAFMD). All vascular
imaging was performed between 8 am and 11 am, on the left
arm, with the participant in a supine position with the fore-
arm extended and slightly supinated. Brachial artery assess-
ments were obtained using high-resolution ultrasound and
a 7.5MHz linear array transducer (Acuson, Sequoia 512),
at baseline (following 10min of supine rest), during five
minutes of forearm occlusion and continuously on r-wave
trigger for 2 minutes following cuﬀ release (hyperemia) as
previously described [14, 15]. Arterial diameter and blood
flow were measured from the digital recordings. Diameters
were determined from the anterior to posterior interface
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between the intimal layers. The percent change in brachial
artery diameter was calculated by the following formula:
(
peak posthyperemia diastolic diameter− baseline diastolic diameter
baseline diastolic diameter
)
∗ 100. (1)
Reproducibility of the BAFMD technique has previously
yielded average mean diﬀerences in brachial artery diameter
change for days, testers, and readers of 1.91%, 1.40%, and
0.21mm, respectively, with intraclass correlation coeﬃcients
of 0.92, 0.94, and 0.90, respectively [15].
(vi) Vascular Stiﬀness was measured by utilizing radial
artery pulse wave analysis (RAPWA) and carotid-posterior
tibial pulse wave velocity (PWV). All artery pressure
waveforms were measured using a Millar tonometer and
processed using dedicated software (SphygmoCor version
8.0, AtCor Medical). The system was used to measure an
averaged radial artery waveform, derive a corresponding
central aortic pressure waveform [16], then calculate pres-
sure augmentation, augmentation index (AIx), and pulse
pressure amplification [17]. For PWV assessment, body
surface distances from the suprasternal notch to the carotid
and tibial sites were measured. Sequential measurements
of arterial pressure waves at these two sites were then
made using the foot-of-the-wave method [18]. The transit
times of each wave were calculated from the onset of the
electrocardiogram QRS complex.
2.5. Statistical Analysis. All analyses were performed by using
the SAS software (v.9.2, SAS Institute, Cary, NC, USA).
Initially, primary outcome data (SBP and DBP) were tested
for normality using quantile-quantile plot. Background
characteristics were compared between the two treatment
groups by using t-test if continuous variables or Fisher’s
exact test if categorical data. Three analytical strategies were
subsequently used: First, changes over time between the
two treatment groups were examined by repeated measure
MANOVA tests and comparison between treatments or visits
were further conducted when there is a significant time
(visit) or treatment eﬀect. Second, changes over time were
examined by trend analysis within each treatment group.
Lastly, simple univariate regression was used to explore the
relationship between changes in each variable with changes
in BP. Variables that showed a significant association in
the simple regression were then included in a multivariate
model. Data collection was complete for all but one of the
twenty participants, who discontinued after the week one
assessment. BP and other outcome data from this participant
were carried forward from week one to the end of week two.
The significance level was set at P < 0.05. All data were
presented as mean ± SD.
3. Results
A total of 20 adult participants with unmedicated stage
1 hypertension completed the study. They averaged
Table 2: Baseline characteristics of study participants.
Characteristics1 All Control DASH
N 20 10 10
Age, yr 44.3± 7.8 42.4± 6.3 46.1± 9.0∗
Female, n 13 6 7
Race, n
Caucasian 5 2 3
African American 14 8 6
Other 1 0 1
BMI, kg/m2 33.9± 6.6 36.9± 6.1 31.0± 5.9∗
Alcohol, serv./wk 1.0± 2.3 1.1± 2.7 0.9± 1.9
SBP, mmHg
(screening)
144.2± 9.38 145.6± 11.5 142.8± 7.03
DBP, mmHg
(screening)
88.5± 6.03 88.2± 5.68 88.8± 6.67
1
Mean ± SD. ∗P < 0.05 comparing to the control group using t-test for
continuous variables and the Fisher exact test for categorical data.
44.3±7.8 yrs of age, had a BMI of 33.9±6.6Kg/m2(consistent
with class I obesity), BP of 144.2 ± 9.38/88.5 ± 6.03mmHg
(Table 2). Among the participants, 13 were females, five
were self-identified Caucasians, 14 were African Americans,
and one was Hispanic. During screening, these participants
reported consuming an average of 1 alcoholic beverage per
week. Despite small sample size, Table 2 demonstrates that
randomized groups were fairly comparable particularly
regarding baseline BP. However, participants in the control
group were younger and heavier in weight (both P < 0.05).
The MANOVA test indicates that there were significant
treatment (dietary pattern) eﬀects on both SBP and DBP
(F = 5.46, P = 0.023 and F = 9.73, P = 0.003, resp.). As
shown in Figure 2, DASH, comparing to baseline, signifi-
cantly reduced SBP at week one (mean change from baseline
−10.65 ± 12.89mmHg, CI :−19.81, −2.49, P = 0.023),
with sustained eﬀect at week two (−9.60 ± 11.23mmHg,
CI :−16.70, −2.50, P = 0.039). Similarly, DASH lowered
DBP to a near-significant degree at week one (−5.95 ±
8.01mmHg, CI : −11.02, −0.88, P = 0.069) as compared to
the baseline, with statistically significant reduction at week
two (−8.60 ± 9.13mmHg, CI :−14.38, −2.82, P = 0.011).
Both SBP and DBP remained constant with exposure to the
control dietary pattern. The diﬀerence between DASH and
control approached statistical significance for SBP at week
one only (P = 0.056) and were statistically significant for
DBP at both week one and week two (P = 0.027 and P =
0.043, resp.).
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Figure 2: Blood pressure changes from baseline by treatment.
As expected based on the nutrient composition of diets,
urinary K+, Mg++, and P increased in the DASH group and
remained relatively unchanged in the controls (Table 3). Uri-
nary K+ increased significantly over time with DASH and the
increases were significantly diﬀerent from that of the con-
trols. The increases in urinary Mg++ and P in the DASH
group were significantly greater than that of the controls at
week one. These findings confirmed adherence to the as-
signed dietary patterns. However, despite increased dietary
Ca, urinary Ca++ did not change with the DASH dietary
pattern, similar to findings of previous DASH studies [1].
3.1. Potential Mechanisms or Mediators. (i) Natriuresis. Uri-
nary Na+ remained relatively constant in both groups (al-
though, however, urinary Na+/K+ ratio decreased signifi-
cantly in the DASH group at both week one and two as
compared to the baseline (Table 4)).
(ii) RAAS. Overall, changes in PRA showed a significant
treatment eﬀect (MANOVA P = 0.004). Table 4 indicates
that PRA showed a tendency to increase in the DASH group
while decreasing in the control group (both NS). The change
in PRA was significantly diﬀerent between the two treatment
groups at week one (P = 0.022), but the diﬀerence was
attenuated at week two (P = 0.071). Similarly, plasma
aldosterone tended to increase in the DASH group, but there
were no significant diﬀerences between the treatment groups.
(iii) Adrenergic tone. Neither urinary norepinephrine
nor epinephrine showed any changes during the study.
(iv) Vascular measurements. Among all the vascular
measurements, plasma nitrite (NO2
−) level following hyper-
emia showed a significant treatment eﬀect (P = 0.014) in
MANOVA (Table 4). Plasma nitrite (NO2
−) after hyperemia
started to show an increase at week one as compared to
the baseline, and the increase was significant at week two
(P = 0.001). This increase was greater than that of the
controls at week two (P = 0.053). This pattern was also ob-
served in the change of plasma nitrite after hyperemia and
that the change in DASH increased significantly at week
two (P = 0.053), whereas there was a significant decrease
within the controls over time (P = 0.026). Similar pattern
was observed in the percent change in plasma nitrite after
hyperemia. Neither BAFMD nor AIx changed during the
course of the study. PWV decreased over time in the DASH
group (trend P = 0.019), and the reduction at week two was
significant compared to baseline (P = 0.026).
In simple linear univariate regressions (Table 5), changes
in urinary Na+ (β = 0.12), K+ (β = −0.19), Na+/K+ ratio
(β = 1.99), and PRA (β = −15.80) showed a significant
association with changes in SBP at week one (all P < 0.05).
Percent change in plasma nitrite after hyperemia also showed
a significant negative association with change in SBP (β =
−0.301, P = 0.035). When the urinary Na+/K+ ratio,
PRA, and percent change in plasma nitrite after hyperemia
were included in a multivariate regression model, all three
variables remained significantly associated with SBP change
(P < 0.05). Similar pattern is observed with DBP change
(data not shown).
4. Discussion
Our data suggest that DASH may lower BP by increasing NO
bioavailability, as measured by plasma nitrite following a
stressor, and possibly has subsequent eﬀects on vascular
basal tone (reduced PWV). There was no evidence that BP
reduction was due to eﬀects of DASH on natriuresis, sup-
pression of the RAAS (as reflected in changes in PRA and
aldosterone), or on adrenergic tone (as reflected in changes in
epinephrine and norepinephrine). Due to small sample size
and other limitations discussed below, these data should be
considered preliminary evidence necessitating further study.
Although our previous research showed that DASH may
shift the pressure-natriuresis curve [3] and that potassium
supplementation leads to natriuresis [19], we saw no clear
evidence of natriuresis. However, the rise in both PRA and
aldosterone suggests a natriuretic eﬀect of DASH. This is
consistent with previous studies that showed an increase in
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Table 3: Adherence measures by treatment and time.
Measurement
Mean ± SD Control DASH P for DASH versus control
Urinary excretion
Potassium, mmol/24 hr
Baseline 46.6± 13.3 42.2± 14.7
Change at week 1 −10.2± 11.9 39.8± 25.8∗ <0.0001
Change at week 2 −7.9± 16.4 25.3± 28.6† 0.005
P for trend 0.367 0.075
Magnesium, mmol/24 hr
Baseline 3.56± 1.54 3.51± 1.20
Change at week 1 0.22± 1.01 1.32± 0.86‡ 0.017
Change at week 2 −0.01± 1.07 0.31± 1.27 0.553
P for trend 0.819 0.454
Phosphorus, mmol/24 hr
Baseline 251.8± 78.82 222.6± 61.22
Change at week 1 7.53± 24.94 82.68± 112.4 0.054
Change at week 2 39.44± 120.6 −35.76± 114.7 0.170
P for trend 0.218 0.446
Urea nitrogen, mol/24 hr
Baseline 3.73± 1.26 3.44± 0.95
Change at week 1 −0.57± 1.01 0.29± 1.04 0.077
Change at week 2 −0.63± 1.32 −0.26± 1.26 0.524
P for trend 0.629 0.780
Calcium, mmol/24 hr
Baseline 36.06± 25.83 39.92± 23.71
Change at week 1 3.75± 16.79 −5.50± 12.75 0.182
Change at week 2 0.55± 14.76 −7.51± 13.41 0.218
P for trend 0.909 0.298
Sodium, mmol/24 hr
Baseline 122.6± 40.82 131.4± 42.83
Change at week 1 19.3± 33.39 −4.2± 57.49 0.278
Change at week 2 17.85± 65.93 −1.5± 64.40 0.620
P for trend 0.493 0.919
∗
P = 0.0004, †P = 0.017, ‡P = 0.002 compared to baseline within treatment group using the MANOVA analysis.
PRA in response to a high intake of K+, a rich component in
DASH [20, 21]. Further, our data suggest that BP-lowering
occurred prior to the week one assessment. Therefore,
it is possible that natriuresis occurred earlier than that
assessment and had reequilibrated by the end of week one.
In fact, potassium supplementation causes natriuresis within
four days [19]. Therefore, we cannot rule out the possibility
that natriuresis contributes to the BP-lowering eﬀect of
DASH, and future studies are needed in which urinary Na
excretion is measured immediately after initiating the DASH
dietary pattern.
Our data do not provide evidence that DASH lowers BP
by direct eﬀects on the RAAS. Renin activity, the rate-limiting
step in generation of the vasoconstrictor angiotensin II,
was actually increased relative to changes in the control
group, possibly due to compensation for lower BP. We did
not measure other RAAS mediators that might reveal a role
of the RAAS; indeed, we know that a polymorphism of the
angiotensinogen gene is associated with the BP response to
DASH [22]. Therefore, a role for the RAAS in mediating BP
lowering with DASH cannot be ruled out, at least in some
genetically predisposed individuals.
Our data also provide no evidence that DASH inhibits the
adrenergic nervous system. Neither urinary norepinephrine
nor epinephrine changed with DASH, but these are fairly
crude measures of adrenergic tone. Changes in adrenergic
tone can be episodic, and multiple urine collections may be
necessary to reflect the change. Indeed, there is evidence of
genetic modulation of the DASH eﬀect by a polymorphism
of the β2-adrenergic receptor gene [22]. Thus an eﬀect of
DASH on adrenergic nervous system regulation of BP cannot
be ruled out.
The increases in stimulated plasma nitrite in DASH re-
lative to controls suggests that the DASH dietary pattern
Journal of Nutrition and Metabolism 7
Table 4: Measures of potential mechanisms by treatment and time.
Measurement
Mean ± SE Control DASH P for DASH versus control
Urinary sodium/potassium ratio
Baseline 2.76± 1.13 3.20± 0.69
Change at week 1 1.23± 2.28 −3.54± 3.52∗ 0.002
Change at week 2 0.61± 1.20 −3.06± 2.91† 0.004
P for trend 0.112 0.018
Plasma renin activity, μg/L·hr
Baseline 0.74± 1.03 0.44± 0.28
Change at week 1 −0.21± 0.30 0.38± 0.63 0.022
Change at week 2 −0.11± 0.24 0.22± 0.46 0.071
P for trend 0.653 0.441
Plasma aldosterone, nmol/L
Baseline 0.35± 0.24 0.32± 0.10
Change at week 1 −0.04± 0.19 0.04± 0.16 0.361
Change at week 2 0.02± 0.22 0.04± 0.17 0.846
P for trend 0.232 0.727
Urinary norepinephrine/Cr, μmol/mol
Baseline 11.38± 5.27 9.39± 3.76
Change at week 1 −0.28± 3.01 0.97± 4.02 0.440
Change at week 2 2.87± 14.50 1.95± 4.64 0.851
P for trend 0.829 0.525
Urinary epinephrine/Cr, μmol/mol
Baseline 1.44± 0.73 1.18± 0.47
Change at week 1 0.07± 0.78 0.21± 0.60 0.668
Change at week 2 −0.14± 0.74 0.60± 1.75 0.231
P for trend 0.713 0.243
NO2
− before hyperemia, μmole
Baseline 286.3± 165.0 279.6± 188.5
Change at week 1 54.36± 91.04 91.6± 166.1 0.564
Change at week 2 67.9± 141.9 65.5± 195.3 0.976
P for trend 0.696 0.163
NO2
− after hyperemia, μmole
Baseline 317.4± 181.1 241.7± 166.6
Change at week 1 −1.90± 69.92 43.59± 53.63 0.141
Change at week 2 5.92± 103.9 93.94± 71.78‡ 0.053
P for trend 0.675 0.036
NO2
− change (absolute), μmole
Baseline 31.04± 60.05 −37.85± 64.89
Change at week 1 −56.26± 59.15 −47.98± 144.7 0.141
Change at week 2 −62.02± 72.5 28.48± 164.7 0.053
P for trend 0.026 0.423
NO2
− change, %
Baseline 12.16± 25.30 −14.84± 15.25
Change at week 1 −19.63± 13.48 −0.80± 23.41 0.053
Change at week 2 −14.11± 37.65 18.12± 38.89 0.093
P for trend 0.004 0.173
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Table 4: Continued.
Measurement
Mean ± SE Control DASH P for DASH versus control
BAFMD peak % change,%
Baseline 5.20± 3.28 6.07± 3.60
Change at week 1 1.64± 1.36 −0.32± 3.99 0.159
Change at week 2 1.47± 3.56 −0.41± 4.94 0.341
P for trend 0.310 0.741
Augmentation index, %
Baseline 22.43± 11.21 19.0± 9.68
Change at week 1 4.17± 6.68 1.0± 5.48 0.348
Change at week 2 3.0± 5.51 2.63± 6.26 0.905
P for trend 0.717 0.270
PWV, m/s
Baseline 9.87± 2.72 10.23± 1.65
Change at week 1 −0.24± 2.22 −0.70± 1.99 0.681
Change at week 2 −0.47± 1.87 −1.54± 2.39‡‡ 0.358
P for trend 0.437 0.019
∗
P = 0.006, †P = 0.015, ‡P = 0.001,‡‡P = 0.026 compared to baseline within treatment group using the MANOVA analysis.
Table 5: Simple regression of SBP changes on changes in individual
biological and vascular variables at week one.
Variable
Week one
Slope P value
Urinary sodium 0.123 0.030
Urinary potassium −0.194 0.018
Urinary sodium/potassium ratio 1.987 0.003∗
Urinary norepinephrine/creatinine −685 0.197
Urinary epinephrine/creatinine −2256 0.376
Plasma renin activity −15.80 0.0003∗
Plasma aldosterone −0.473 0.312
Plasma nitrite after hyperemia, % −0.301 0.035∗
Brachial artery flow-mediated dilation 0.021 0.982
Augmentation index, % 0.736 0.174
Pulse wave velocity, m/s −0.184 0.905
∗
Since urinary sodium and urinary potassium are closely related with
urinary sodium/potassium ratio, only urinary sodium/potassium ratio,
plasma renin activity, and % change in plasma nitrite after hyperemia were
further included in a multivariate regression model. All three variables
remained significantly associated with SBP change at week one (P < 0.05 for
all).
may improve the vascular endothelium’s ability to up-regu-
late NO, in response to a localized stressor. The DASH
dietary pattern contains nuts which are a good source of L-
arginine, a precursor of nitric oxide (NO) [23, 24]. Oxidative
stress and endothelial dysfunction have been implicated in
hypertension [25]. Previous studies have also shown that
foods/diets rich in antioxidants, L-arginine, and marine n-3
fatty acids, such as DASH, may also improve vascular reac-
tivity [26–28]. In a behavioral intervention study, following
the DASH dietary pattern enhanced antioxidant capacity
and prevented worsening of endothelial function during
acute hyperlipidemia induced by intralipid infusion among
obese hypertensives [29]. The authors attributed the vascular
protection eﬀect to the rich antioxidants in the DASH dietary
pattern. In our study we did not observe an increase in
BAFMD following the DASH diet. This may be related to
the limited sample size in each group and relatively short
assessment period. Another trial also did not observe an
impact of consuming the DASH diet for 30 days on vascular
function including measurement of FMD [30]. However,
dietary adherence of these participants to the DASH
pattern was not reported. A recent study, nevertheless, show-
ed that consuming the DASH diet for 3 weeks improved en-
dothelial function as indicated by small artery elasticity [31].
The changes in plasma nitrite (the primary metabolite of
vascular NO production) suggest an increase in NO bio-
availability and may change prior to the physiological res-
ponse. It is possible that the BP-lowering eﬀect of DASH
could be mediated through its eﬀects of antioxidants on
NO consumption. In a high antioxidant environment, it is
possible that more NO produced would be oxidized to nitrite
rather than nitrate and peroxynitrite. In addition, eﬀects
of DASH on NO bioavailability and metabolism may have
implications for cardiovascular health aside from just BP
control. Future studies should examine the direct impact of
the DASH dietary pattern on vascular health.
The possibility that the BP-lowering eﬀect of DASH may
be mediated through its impact on the vascular endothelium
is further suggested by the observed reduction in PWV. Pre-
vious research has shown that PWV is an independent
predictor of increasing SBP over time and of incident hyper-
tension among people with normotension or untreated hy-
pertension, respectively [32]. Our study suggests that arterial
stiﬀening, as indicated by PWV, may be an underlying cause
of the rise in BP. In addition, PWV was found to be a
strong and independent predictor of CVD mortality with
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high performance values among hypertensive and diabetic
patients [33, 34]. For every 1m/s increase in PWV, the hazard
ratio for all-cause and CVD mortality increases by 8% [34].
Thus, even if the impact of the DASH dietary pattern on
PWV was not related to the mechanism for BP reduction, its
potential benefit on CVD mortality via this marker deserves
further examination and confirmation.
The urinary Ca2+ data may suggest another possible BP-
lowering mechanism. As noted above, urinary Ca2+ re-
mained unchanged in both treatment groups despite a much
higher intake in the DASH group than in the controls. Our
previous study showed that the combined eﬀects of higher
potassium and low acid load of the DASH diet may con-
tribute to Ca retention and subsequent reduced bone turn-
over [35]. Thus conservation of Ca likely occurred within
the DASH group, which may have contributed to the BP
reduction through vascular eﬀects of Ca. This possibility also
deserves further investigation.
This study is limited primarily by the small sample size.
A controlled feeding protocol, which was used in, and is one
of the strengths of, this study allows for near-absolute con-
trol over nutrient intake in humans, eliminating extensive
confounding that occurs in studies in which participants
select and prepare their own meals. However, feeding studies
are limited by the resources required and participant burden.
Nonetheless, large feeding studies with adequate power are
feasible [1, 2, 36]. Our data suggest that such a study would
be valuable in definitively determining eﬀects of DASH on
NO bioavailability, oxidative stress, antioxidant capacity, as
well as eﬀects on other BP mediators in the RAAS on the
adrenergic nervous system, and at earlier time points when
BP is going down.
This study sheds light on the possible mechanism(s)
through which the DASH dietary pattern lowers BP. Confir-
mation in larger populations, evaluation of other potential
mediators, and a deeper understanding of molecular mech-
anisms and pathways are needed. Understanding the BP-
lowering mechanisms of DASH can lead to more refined
nutritional recommendations, the identification of new drug
targets, greater insight into normal and abnormal BP regula-
tion, and more targeted treatments for individual patients.
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